CA
NZ
UK
AU
IND
US
Jon Blotner, President of Commercial and Operations at Wayfair Inc. (NYSE:W), filed a Form 4 on September 10, 2026, disclosing the sale of 6,968 shares of Class A Common Stock on September 8, 2026.
A Form 4 filed on September 10, 2026 discloses that Christian Stephane Mumenthaler, a director of MetLife, Inc. (NYSE:MET), acquired 21 shares of common stock on September 8, 2026 through dividend reinvestment on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
Ramy Tadros, President of U.S. Business at MetLife, Inc., filed a statement of changes in beneficial ownership on September 10, 2026, reporting an acquisition of common stock on September 8, 2026.
A Form 4 filed on September 10, 2026 disclosed that Oluwadara Johnson Treseder, a director of Robinhood Markets, Inc. (NASDAQ:HOOD), sold 1,875 shares of Class A Common Stock on September 8, 2026 under a pre-established Rule 10b5-1 trading plan.
Rajiv Patni, Chief Medical Officer of Septerna, Inc., filed a Form 4 on September 10, 2026, disclosing the acquisition of a stock option covering 275,000 shares of common stock on September 8, 2026.
Dana Eschenburg Perez, Chief Accounting Officer of Sharplink, Inc. (NASDAQ:SBET), filed a Form 4 on September 10, 2026, reporting a share withholding transaction dated September 9, 2026, related to the vesting and settlement of restricted stock units.
A Form 4 filed on September 10, 2026 discloses that Camilla Languille, a director of GlobalFoundries Inc., had 5,235 restricted stock units vest and settle into ordinary shares on September 8, 2026, with 1,571 shares withheld by the issuer for tax obligations.
Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), filed a Form 4 on September 10, 2026, disclosing transactions in common stock and restricted stock units dated September 8, 2026.
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, Inc., filed a Form 4 on September 10, 2026, reporting transactions in the company's common stock on September 8, 2026, related to the vesting of restricted stock units.
Frederick G. Vogt, Interim CEO and General Counsel of Iovance Biotherapeutics, Inc., filed a Form 4 on September 10, 2026, reporting transactions in common stock and restricted stock units dated September 8, 2026.
Please wait processing your request...